Welcome to our dedicated page for Endo news (Ticker: NDOI), a resource for investors and traders seeking the latest updates and insights on Endo stock.
Endo, Inc. (OTCQX: NDOI) delivers specialty pharmaceutical solutions through branded therapies, generics, and sterile injectables. This news hub provides investors and industry professionals with timely updates on material developments shaping the company’s trajectory.
Track Endo’s latest press releases including earnings reports, regulatory milestones, clinical trial progress, and strategic initiatives. Our curated feed covers FDA decisions, manufacturing expansions like the Indore facility, and advancements in treatments for musculoskeletal conditions such as Dupuytren's contracture.
Key updates include financial disclosures, product pipeline developments, and operational efficiency measures. Stay informed about Endo’s clinical research presentations, supply chain optimizations, and compliance achievements that demonstrate its commitment to quality therapeutics.
Bookmark this page for centralized access to verified NDOI news. Check regularly for insights into how Endo’s diversified portfolio and patient-centric approach position it within the evolving pharmaceutical landscape.
Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.
The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.
Endo (OTCQX: NDOI) has announced the launch of a Spatial Computing Injection Simulator for Peyronie's disease, set to debut at the American Urological Association Annual Meeting (April 26-29, 2025). The innovative simulator combines physical penile models with digital content through an Apple Vision Pro app, creating an immersive learning environment for urology specialists.
The 20-minute training experience helps healthcare providers refine their injection technique for XIAFLEX®, the only FDA-approved nonsurgical treatment for Peyronie's disease. The simulator offers hands-on practice for product reconstitution, injection angles, procedure demonstrations, and post-injection process information.
This marks Endo's second venture into spatial computing for medical training, following a previous development for hand specialists treating Dupuytren's contracture. The company collaborated with technology agency Lucid Dream to develop the Apple Vision Pro application.
Endo (OTCQX: NDOI) has scheduled the release of its first quarter 2025 financial results for May 7, 2025, before the market opens. The company will hold a conference call at 8:30 a.m. ET on the same day.
Investors can access the audio webcast through the company's Investor Relations website at investor.endo.com under Events & Presentations. For those joining via phone, the dial-in numbers are 800-836-8184 (U.S. and Canada toll-free) and 646-357-8785 (international). Participants should connect 10 minutes before the scheduled start time. A webcast replay will be made available after the event.
Endo (OTCQX: NDOI) has launched the Spatial Computing Injection Simulator, becoming the first pharmaceutical company to introduce an external spatial computing program. The simulator, utilizing Apple Vision Pro technology, creates an immersive learning environment for hand specialists administering XIAFLEX®, the only FDA-approved nonsurgical treatment for Dupuytren's contracture.
The 20-minute experience combines physical hand models with digital content, allowing healthcare providers to practice reconstitution, injection angles, and post-injection procedures. The technology has already garnered significant interest at medical conferences, with over 600 hand specialists testing it at the American Society for Surgery of the Hand (ASSH) and American Association for Hand Surgery (AAHS) annual meetings.
The simulator is now available through Endo's orthopedics sales team, developed in partnership with technology agency Lucid Dream for the Apple Vision Pro platform.
Endo (OTCQX: NDOI) announced the presentation of data regarding XIAFLEX® (collagenase clostridium histolyticum) for treating recurrent Dupuytren contracture after surgical correction at the IFSSH and IFSHT Triennial Congress (March 24-28, 2025).
Dupuytren contracture, affecting an estimated 17 million Americans, is a progressive hand condition where collagen cords form under the palm's skin, causing fingers to pull inward. The Phase 4 retrospective study data explores XIAFLEX® as an alternative to repeat surgery for patients experiencing recurrent deformity after initial successful surgery.
Dr. Clayton A. Peimer, Adjunct Clinical Professor of Orthopedics at Brown University's Warren Alpert Medical School and lead study author, emphasized the importance of these findings for healthcare providers managing recurrent cases of Dupuytren contracture.
Endo (NDOI) reported its Q4 and full-year 2024 financial results, with Q4 revenues of $467 million, down 6% from $498 million in Q4 2023. The company posted a Q4 2024 net loss of $349 million, compared to a $2,441 million loss in Q4 2023.
Key highlights include XIAFLEX® achieving record revenues of $516 million in 2024, up 9% versus 2023. The company launched three sterile injectable products, including ADRENALIN® ready-to-use premixed bags. Segment performance showed Branded Pharmaceuticals at $247 million, Sterile Injectables at $92 million, and Generic Pharmaceuticals at $111 million.
Endo provided 2025 guidance with expected revenues of $1,775 to $1,860 million and adjusted EBITDA of $620 to $650 million. The company also announced a definitive agreement to combine with Mallinckrodt plc in a cash and stock transaction.
Mallinckrodt and Endo have announced a strategic merger to create a global pharmaceuticals leader through a stock and cash transaction. The deal, expected to close in H2 2025, will see Endo shareholders receive $80 million in cash and own 49.9% of the combined entity, while Mallinckrodt shareholders will own 50.1%.
The combined company, to be listed on the NYSE, projects $3.6 billion in 2025 revenue and $1.2 billion in Adjusted EBITDA. The merger aims to generate at least $150 million in annual operating synergies by Year 3 and approximately $75 million in Year 1.
Key aspects include a net leverage of 2.3x at close, 17 manufacturing facilities, 30 distribution centers, and approximately 5,700 employees. The companies plan to combine and later separate their generics and sterile injectables businesses. Siggi Olafsson will serve as CEO of the combined entity, with Paul Efron as Board Chair.
Endo (OTCQX: NDOI) has announced the presentation of a post hoc data analysis from a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for Peyronie's disease at the 89th annual SESAUA meeting, March 12-15, 2025.
The analysis, presented by Dr. Gregory A. Broderick, suggests that CCH could be a viable alternative to watchful waiting for Peyronie's disease patients, regardless of their disease phase or pain status. The research specifically examines the potential benefits of CCH treatment in patients with penile pain at baseline.
The Endo-supported study involves multiple researchers, including specialists from various medical institutions, focusing on expanding treatment options for Peyronie's disease patients beyond current literature recommendations.
Endo (OTCQX: NDOI) has announced the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc. for up to $99 million. The deal structure includes an $84 million upfront cash payment and potential additional $15 million in milestone-based payments.
Knight Therapeutics, specializing in innovative prescription pharmaceuticals in Canada and Latin America, will acquire Paladin Pharma, Endo's Canada-based specialty pharmaceutical subsidiary. The transaction, subject to regulatory approvals including Canadian anti-trust clearance, is expected to close in mid-2025.
FAQ
What is the current stock price of Endo (NDOI)?
What is the market cap of Endo (NDOI)?
